.Merck & Co.'s TIGIT plan has gone through an additional obstacle. Months after shuttering a peri...
.After a year specified by pipe cuts, the departure of its chief executive officer as well as cutbac...
.Cullinan Therapeutics was actually thrilled enough with Harbour BioMed's bispecific invulnerable re...
.In this week's episode of "The Best Line," our experts're diving into Tough Biotech's annual Strong...
.The confetti is still flying coming from Eli Lilly's celebration celebrating the approval of Alzhei...
.Accept to recently's Chutes & Ladders, our summary of notable management hirings, shootings and ...
.Adhering to an inadequate revealing for Lykos Therapies' MDMA candidate for post-traumatic stress d...
.AN2 Therapeutics is actually reconsidering its own service in response to lackluster midphase data,...
.Merck & Co. is actually paying for $700 thousand beforehand to test Amgen in a blood cancer cell...
.With Gilead Sciences on the verge of an FDA choice for its own liver illness medication seladelpar,...